THE DRUG WAR HAS TWO SIDES OF THE BORDER. THE MONEY CROSSES BOTH.

VAULT · BORDERS, BOMBS & BAD DECISIONS

Published by | Langhorne P. Breedlove

MONDAY, NOVEMBER 9, 2026 · 2:43 AM ET

Tags: Drug Markets · U.S. Demand · Organized Crime · Fentanyl · Firearms Trafficking · Public Health

Dear fellow American proletariat: America has spent decades explaining that dangerous drugs come from somewhere else. Very well. But who purchases them? Who launders the proceeds, supplies the weapons, consumes the product, and eventually calls a neighboring country a failed state for allowing the industry to exist? Apparently the market has a foreign supply chain and a mysteriously invisible American customer.

This is not a defense of drug cartels or an argument that every drug user bears the same responsibility as an armed trafficker. It is a question about shared causation. Illicit demand, criminal profits, coercion, weapons, corruption, unequal opportunities, public-health failures and international policy interact. A serious analysis must distinguish the person with a substance use disorder from a criminal organization profiting through intimidation.

ROOTS · THE DRUG MARKET DID NOT STOP AT THE BORDER

Modern international drug control emerged through treaties governing production and trade, including the 1961 Single Convention on Narcotic Drugs and the 1988 United Nations convention against illicit traffic. National governments retain distinct criminal laws, public-health institutions and enforcement obligations under those arrangements. A treaty against illicit trafficking is not proof that every punitive tactic has worked or that all psychoactive substances present identical harms. (Source 01)

Drug markets reorganize when their inputs, routes and customers change. In its 2025 National Drug Threat Assessment, the Drug Enforcement Administration identified major Mexican trafficking organizations as suppliers of illicit fentanyl and methamphetamine entering the United States. These organizations rely on international chemical procurement, laboratories, transport, domestic distribution and financial networks. The United States is not simply a spectator at the far end of that chain: the domestic market supplies its revenue. (Source 02)

Cocaine moves through a partly different geography. The United Nations Office on Drugs and Crime's 2026 World Drug Report identifies major trafficking routes from South America to North America and Europe, with different departure, transit and destination countries. That record does not support treating every Latin American nation as an identical producer or every Caribbean island as a criminal corridor. (Source 03)

TODAY · PEOPLE ARE DYING, AND THE NUMBERS HAVE CHANGED

CDC's May 13, 2026 provisional estimate counted 69,973 U.S. drug overdose deaths during 2025, down almost 14% from an estimated 81,313 in 2024. Estimated opioid-involved deaths fell from 55,296 to 44,564. These provisional counts may change as death certificates are completed and do not establish which individual policies caused the decline. (Source 04)

The same CDC release estimated 38,084 deaths involving synthetic opioids, 26,181 involving psychostimulants and 19,581 involving cocaine in 2025. These categories overlap because one death can involve multiple drugs; adding them together would exaggerate the national total. The decline is encouraging evidence of change but leaves an enormous preventable mortality burden. (Source 04)

The 2025 National Survey on Drug Use and Health estimated 26.0 million people aged 12 or older experienced a drug use disorder that year and 44.6 million experienced an alcohol or drug use disorder. Drug use, misuse, dependency and trafficking are different categories. A person struggling with dependency is not automatically a supplier or organizer of transnational crime. (Source 05)

GAO's December 2025 review found that Mexican criminal networks used precursor chemical suppliers, production facilities and cross-border trafficking routes to move fentanyl and methamphetamine into the United States, coordinating with domestic groups and laundering proceeds through multiple channels. These findings describe major identified networks, not every cross-border shipment or every Mexican business. (Source 06)

THE AMERICAN SIDE OF THE WEAPONS MARKET

GAO reported in September 2026 that the Bureau of Alcohol, Tobacco, Firearms and Explosives traced 122,084 firearms recovered in Mexico from January 2020 through December 2024; 82,785, or 68%, were identified as U.S.-sourced. A U.S. source includes certain weapons made or legally imported in the United States, not necessarily a firearm directly sold illegally by its first retail seller. The recovered and submitted weapons are not a random sample of all firearms used in Mexican crimes. (Source 07)

GAO also reported 4,944 firearms seized by Customs and Border Protection while bound for Mexico through land ports of entry between January 2020 and December 2025. Officials identified gaps in data collection and tracking that hampered effective enforcement. A country concerned about weapons in the hands of cartels must examine the outbound trade as carefully as the inbound drugs. (Source 07)

WHO PROFITS? WHO PAYS?

Trafficking organizations generate revenues from consumers and use portions of those proceeds for transport, corruption, procurement, violence and reinvestment. The costs are distributed differently: families lose loved ones, communities face intimidation, governments fund enforcement and medical response, and vulnerable people can be coerced into illicit activity. These are not interchangeable harms and cannot be attributed to one country in one convenient percentage.

Drug violence can also persist independent of changing consumer demand because criminal groups compete over routes, extortion, other contraband and local territory. Weak judicial institutions, collusion and weapons availability matter. Treating all cross-border violence as a simple consequence of American addiction would erase the agency of armed organizations and the duties of governments responsible for protecting their populations.

FIVE QUESTIONS THE POLICY MUST ANSWER

01 · REDUCING DEMAND WITHOUT CRIMINALIZING ILLNESS

Treatment capacity, prevention, overdose reversal, recovery support and management of co-occurring conditions should be assessed with clinical evidence. SAMHSA's 2024 survey reported that only about 19.3% of people classified as needing substance use treatment received it that year. That treatment-gap estimate is not identical to 2025 prevalence and must not be presented as a 2026 treatment rate. (Source 08)

02 · TARGETING VIOLENT TRAFFICKING NETWORKS

Investigations should focus on organized violence, money laundering, coercion, corruption, illicit procurement and unlawful distribution, with lawful evidence gathering and judicial review. Criminal prosecution and international cooperation have roles that public-health treatment cannot replace. A credible program should distinguish low-level possession from leadership in violent trafficking networks.

03 · TRACKING MONEY & WEAPONS

Agencies should improve tracing, customs intelligence, beneficial-ownership information and financial investigations, subject to privacy and due-process safeguards. Trace data are investigative leads, not a complete census of criminal weapons. Anti-money-laundering controls should be evaluated for useful interdictions and false positives, not by counting reports filed.

04 · WORKING WITH SOVEREIGN NEIGHBORS

Cooperation with Mexico, Caribbean countries, South American governments and other partners must respect domestic laws and legitimate sovereignty. Evidence sharing, extradition, forensic support, anti-corruption collaboration and financial oversight can be negotiated without claiming the United States has authority to govern another country's territory. Regional organizations and affected communities should be treated as participants, not scenery.

05 · MEASURING THE HUMAN OUTCOME

An increase in seizures may reflect better enforcement, larger supply, changed routes or all three. Arrest counts alone do not establish reductions in addiction, violent crime or financial power. Evaluate overdose deaths and injuries, treatment access, organized-crime violence, weapon tracing, prosecution integrity, judicial outcomes, corruption exposure and community trust on separate dashboards.

WHAT THE EVIDENCE DOES & DOES NOT PROVE

There is documented U.S. demand, documented transnational supply and documented U.S.-sourced weapons among firearms traced after recovery in Mexico. That supports examining responsibility across borders. It does not prove that every U.S. drug purchase directly finances a particular cartel, that all Mexican firearms originated in the United States, or that one enforcement strategy explains the 2025 decline in overdoses. (Sources 04, 06, 07)

People disagree about the appropriate mix of prohibition, decriminalization, regulated markets, treatment and international enforcement. Arguments differ by substance and jurisdiction. Cannabis regulation, for example, does not provide an automatic model for the high-risk illicit fentanyl market; nor does a criminal penalty for all consumers automatically dismantle supply organizations. The strongest analysis compares evidence for specific interventions while protecting public safety and civil liberties.

THE LEGAL PATH & TEN-YEAR LEDGER

Congress finances and regulates federal drug-control, health and border programs within its powers. DOJ, DEA, DHS, Treasury and HHS administer distinct criminal, customs, financial and clinical functions. State and Tribal laws govern other aspects of public safety and healthcare, while international operations require separate legal authority and partner-country arrangements. A proposed reallocation cannot simply transfer every enforcement dollar to treatment by presidential announcement.

The first-year ledger must classify existing spending by prevention, treatment, harm reduction, interdiction, investigation, prosecution, detention, financial enforcement and international assistance. Add clearly specified new workforce, public-health and intelligence programs, and identify any costs shifted among federal, state and foreign governments. The price of a seizure is not the market value of a drug shipment, and neither is automatically a federal saving.

A ten-year model should compare continuation of current programs with a prevention-and-treatment expansion, targeted network disruption, and a combined strategy. Estimate implementation, clinical capacity, procurement, intelligence and oversight costs; then separately assess mortality, health outcomes, violence and corruption. Savings from reduced emergency care or detention must be tied to demonstrable service reductions, not assumed from a national percentage.

AP's first-year net cost and ten-year balance remain unknown until the proposed program, enrollment, enforcement responsibilities and international commitments are specified. Human benefits and changes in drug-market revenue should not be converted into imaginary Treasury receipts.

WHY IT MATTERS

The United States can demand that neighboring governments confront criminal organizations while also accepting responsibility for its own illicit markets, financial channels, firearms diversion and unmet treatment needs. Those obligations are not mutually exclusive. They involve different institutions and require honest measurement.

A person in recovery is not a cartel. A country is not a cartel. And a border is not a moral force field through which American money passes without consequences. The goal is fewer deaths, less coercion, safer communities and governments capable of describing who did what—not another decade of declaring victory over a shipment while leaving the market untouched.

SOURCES & FURTHER READING

01 · United Nations Office on Drugs and Crime — International Drug Control Conventions, historical treaty framework. https://www.unodc.org/unodc/en/commissions/CND/conventions.html

02 · Drug Enforcement Administration — 2025 National Drug Threat Assessment, May 13, 2025. https://www.dea.gov/documents/2025/2025-05/2025-05-13/national-drug-threat-assessment

03 · United Nations Office on Drugs and Crime — World Drug Report 2026, cocaine trafficking data. https://data.unodc.org/wdr2026?page=51

04 · Centers for Disease Control and Prevention — U.S. Overdose Deaths Decrease for Third Consecutive Year in 2025, May 13, 2026. https://www.cdc.gov/nchs/pressroom/releases/20260513.html

05 · Substance Abuse and Mental Health Services Administration — 2025 National Survey on Drug Use and Health, July 27, 2026. https://www.samhsa.gov/newsroom/press-announcements/20260727/samhsa-releases-annual-national-survey-on-drug-use-and-health

06 · U.S. Government Accountability Office — Illicit Synthetic Drugs: Trafficking Methods, Money Laundering Practices, and Coordination Efforts, GAO-26-107918, December 18, 2025. https://www.gao.gov/products/gao-26-107918

07 · U.S. Government Accountability Office — Firearms Trafficking to Mexico: Better Data and Performance Monitoring, GAO-26-108061, September 2026. https://www.gao.gov/products/gao-26-108061

08 · Substance Abuse and Mental Health Services Administration — 2024 NSDUH National Findings, July 28, 2025. https://www.samhsa.gov/newsroom/press-announcements/20250728/samhsa-releases-annual-national-survey-on-drug-use-and-health

10 RECOMMENDED ARTICLES, ESSAYS & POLICIES

→ Explore Migration Drivers: Foreign Policy, Displacement & Climate

→ Explore Latin American & Caribbean Sovereignty & Regional Autonomy

→ Explore Immigration, Asylum & Citizenship

→ Explore Redesign the Faces of American Currency

→ Explore Ferries, Locks & Public Waterways

→ Explore Anti-Epsteins

→ Explore Libertarians

→ Explore Outlaws, Pirates & Folklore

→ Explore Reformers, Abolitionists & Civil Rights

→ Explore Replace All People Featured On US Currency

WE ARE ONE.  ·  E PLURIBUS UNUM.